• Arrhythmia-induced cardiomyopathy
• Heart failure (acute and chronic)
• Atrial fibrillation
• Ischemic cardiomyopathy
• Lipid disorders
• Hypertension
• Stroke (cerebrovascular accidents – CVA)
• Venous disease

Solid tumors & hematologic cancers:

• Apoptosis: focus on the resistance of cancer cells to programmed death
• Immunotherapy: mobilization of T-cells against tumors with allogeneic CAR-T cells
• Protein-protein interactions: new high-potential targets

Drug candidates:

• That demonstrate signs of clinical activity
• Preferably against malignant gastrointestinal and hematological tumors

<ul class=”blue-list”>
<li>Type 1 and type 2 diabetes</li>
<li>Diabetic kidney disease (DKD)</li>
<li>Non-alcoholic steatohepatitis (NASH) and metabolic syndrome</li>
<li>Diabetic retinopathy</li>
</ul>
Any innovative product in late-stage clinical trials demonstrating promising value to diabetic patients.

In research phase:

• Alzheimer disease
• Parkinson disease
• Diseases that specifically modify beta-amyloid, TAU and alpha-synuclein proteins

In development phase:

• Neurology:
  • Alzheimer disease
  • Parkinson disease
  • Multiple sclerosis
  • Neurovascular disorders
  • Other: Cerebral trauma, amyotrophic lateral sclerosis (ALS), Huntington disease, neuropathic pain
• Psychiatry:
  • Autism
  • Schizophrenia

In research phase:

• Modulation of immune effector cells activation with specific focus on T cells and B cells

In development phase:

• Immune-inflammatory and autoimmune diseases with a focus on Lupus, primary Sjögren’s syndrome, and systemic sclerosis
• Interest in other indications in this field, especially involving an unmet therapeutic need and/or similar pathophysiological mechanism
• Targeted molecules whose therapeutic approach is supported by biomarkers and/or a mode of action